Articles related to Oncology, Medical

A discussion between an oncologist and a patient, Evelyn, a transgender woman with prostate cancer who was able to change the doctor’s binary view of gender thanks to a candid conversation and the help from a dozen eggs – brown and blue.

This Q&A with Dana Farber’s Dr. Rinath Jeselsohn centers on fulvestrant (Faslodex, AZ) and its current role in the management of breast cancer, as well as outlining the emerging selective estrogen receptor degraders (SERDs), their clinical trial data, potential for use, and whether the options will become the “backbone” of endocrine therapy in HER2-negative metastatic breast cancer.

An oncologist pens an essay about his 10-year-old son who died in March 2021 from diffuse midline glioma, providing a glimpse into his own extreme truths about the burden he carries in treating cancer patients.

Publication: JAMA OncologyMethod: Retrospective study of 160 adults with hematologic malignant disease who were vaccinated with 1 of 3 COVID-19 vaccines (February through April 2021).Results: Patients receiving B-cell-depleting immunotherapy may not gain adequate protection from vaccination and may still develop a potentially fatal infection.

Bookmark this page – or download the information directly, if you prefer – to ensure you’re always connected to the latest and greatest information on the very best in NSCLC treatment regimens (NCCN Guidelines).

Source: Blood AdvancesKey Points: In a cohort of 154 patients with NHL or MM receiving CAR T-cells, clonal hematopoiesis of indeterminate potential (CHIP) was present in 48%. Although associated with worse prognosis in these patients receiving autologous transplantation, no such association was seen in these patients receiving CAR T. Instead, the authors saw increased rates of complete response and cytokine release syndrome severity in the younger than 60 population. However, there was no difference in progression-free or overall survival, regardless of age. Design: Cohort review of 154 patients with NHL or MM receiving CAR T-cells